Shield surfaces what to watch. Command answers what to do next. Each signal in your queue arrives with adversarial validation already complete — PROCEED, DELAY, or KILL — sourced to its primary evidence and confidence-scored before it reaches your inbox.
Dataset-level totals across the curated corpus — PubMed/NCBI, U.S. FDA, ClinicalTrials.gov, and SEC EDGAR. Counts reflect the most recent scheduled compile — a curated snapshot, not a streaming source.
Review a dossier sample, then request your dossier setup so we can scope the indication areas and competitors your team needs covered. That is what turns Shield from "active" into a working paper trail.
Next tier — Command: adds organization-wide configuration and a dedicated point of contact, built for teams running multiple programs. Command is sales-assisted — talk to us to scope it.
Your verdict engine, team vault, and Atlas access switch off, and dossier and competitor monitoring stop moving toward activation. Everything your team has already saved stays exportable while your plan is active — pull anything you need to keep before the period ends.
Share a dossier sample with a colleague who owns a competing or adjacent program — it is the clearest demonstration of what Shield produces.
AimwellBio provides decision-support intelligence. It is not medical, legal, regulatory, or investment advice. Sources and outputs should be reviewed by qualified professionals before action.